These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 8692977)
21. Influence of follicular dendritic cells on HIV dynamics. Hlavacek WS; Stilianakis NI; Perelson AS Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1051-8. PubMed ID: 11186306 [TBL] [Abstract][Full Text] [Related]
22. Viral dynamics in human immunodeficiency virus type 1 infection. Wei X; Ghosh SK; Taylor ME; Johnson VA; Emini EA; Deutsch P; Lifson JD; Bonhoeffer S; Nowak MA; Hahn BH Nature; 1995 Jan; 373(6510):117-22. PubMed ID: 7529365 [TBL] [Abstract][Full Text] [Related]
23. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903 [TBL] [Abstract][Full Text] [Related]
24. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093 [TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of viral dynamics and genotypes in hepatitis B virus. Locarnini SA J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S322-8. PubMed ID: 12472957 [TBL] [Abstract][Full Text] [Related]
26. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. Nowak MA; Bonhoeffer S; Shaw GM; May RM J Theor Biol; 1997 Jan; 184(2):203-17. PubMed ID: 9059598 [TBL] [Abstract][Full Text] [Related]
27. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Ho DD; Neumann AU; Perelson AS; Chen W; Leonard JM; Markowitz M Nature; 1995 Jan; 373(6510):123-6. PubMed ID: 7816094 [TBL] [Abstract][Full Text] [Related]
28. Dynamics of an HIV Model with Multiple Infection Stages and Treatment with Different Drug Classes. Wang X; Song X; Tang S; Rong L Bull Math Biol; 2016 Feb; 78(2):322-49. PubMed ID: 26842389 [TBL] [Abstract][Full Text] [Related]
30. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. Locarnini S; Birch C J Hepatol; 1999 Mar; 30(3):536-50. PubMed ID: 10190742 [No Abstract] [Full Text] [Related]
31. Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa. Boyd A; Houghtaling L; Moh R; Chekaraou MA; Gabillard D; Eholié SP; Anglaret X; Zoulim F; Danel C; Lacombe K; For The Anrs Trivacan And Anrs VarBVA Studies Am J Trop Med Hyg; 2017 Dec; 97(6):1936-1942. PubMed ID: 29141712 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. Puoti M; Airoldi M; Bruno R; Zanini B; Spinetti A; Pezzoli C; Patroni A; Castelli F; Sacchi P; Filice G; Carosi G AIDS Rev; 2002; 4(1):27-35. PubMed ID: 11998781 [TBL] [Abstract][Full Text] [Related]
33. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Delaney WE; Locarnini S; Shaw T Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320 [TBL] [Abstract][Full Text] [Related]
34. A model of HIV-1 pathogenesis that includes an intracellular delay. Nelson PW; Murray JD; Perelson AS Math Biosci; 2000 Feb; 163(2):201-15. PubMed ID: 10701304 [TBL] [Abstract][Full Text] [Related]
35. Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. Karlsson AC; Birk M; Lindbäck S; Gaines H; Mittler JE; Sönnerborg A AIDS Res Hum Retroviruses; 2001 Mar; 17(5):409-16. PubMed ID: 11282009 [TBL] [Abstract][Full Text] [Related]
36. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR; Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101 [TBL] [Abstract][Full Text] [Related]
37. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. Maida I; Ríos MJ; Pérez-Saleme L; Ramos B; Soriano V; Pegram PS; Mura MS; Sánchez-Margalet V; Saldívar-Cornejo I; Wilkin A; Babudieri S; Núñez M AIDS Res Hum Retroviruses; 2008 May; 24(5):679-83. PubMed ID: 18462085 [TBL] [Abstract][Full Text] [Related]
38. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093 [TBL] [Abstract][Full Text] [Related]
39. [Antiviral strategies in the replication of human immunodeficiency virus]. Wainberg MA; Bour S; Geleziunas R; Bentwich Z Union Med Can; 1992; 121(5):307-9, 312-4. PubMed ID: 1279875 [TBL] [Abstract][Full Text] [Related]
40. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Hu Y; Cheng X; Cao F; Huang A; Tavis JE Antiviral Res; 2013 Sep; 99(3):221-9. PubMed ID: 23796982 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]